![](/wp-content/uploads/2018/10/MBqrEZ1tTXuvq4EaPRhp.png)
$599
Novo Resubmits 2.0mg High-dose Ozempic to FDA
Novo Nordisk announced it has resubmitted the sNDA to FDA for QW high-dose 2.0mg injectable semaglutide for the treatment of T2DM. Recall, in March 2021, Novo announced it received a Refusal to File letter from FDA (previous FENIX insight) after initially filing the application on January 20, 2021 (previous FENIX insight). Below, FENIX provides thoughts on the refiling.